RxDoctor Payments Data

James Grantham, MD

Interventional Cardiology · Kansas City, MONPI 1134185390

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Boston Scientific at 44.1% of the total. Reporting peaked in 2021 at $98,165 and has fallen 66.4% since, to $32,971 in 2025. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$357,184in general payments, 2019–2025

Across 355 payments — averaging $1006.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$157K
  • Siemens Medical Solutions USA, Inc.$109K
  • Asahi Intecc USA, Inc.$35K
  • Abbott$16K
  • Medtronic$14K
  • Teleflex LLC$11K
  • plus $15K from 9 others
$1,245,846in research payments, 2019–2025

Across 55 payments — averaging $22,652 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$1.2M
  • Arrow International, Inc.$8K
  • Abbott$4K
  • Asahi Intecc USA, Inc.$1K

What the payments were for

  • Consulting fees$138,77039%
  • Speaking & faculty fees$193,00654%
  • Travel & lodging$7,3712%
  • Food & beverage$18,0365%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$357,184 in reported general payments places this provider in the 95th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$167,687
Medicare patients
643
Services billed
1,423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArcalystRilonacept13$299,710
EliquisApixaban152$192,698
JardianceEmpagliflozin105$109,981
XareltoRivaroxaban56$73,124
Repatha SureclickEvolocumab55$51,729
EntrestoSacubitril/Valsartan18$14,974
BrilintaTicagrelor15$9,229
Ranolazine ErRanolazine76$7,556
Ezetimibe194$4,395
Rosuvastatin Calcium303$3,756
Metoprolol Succinate262$3,275
Atorvastatin Calcium359$2,980
ClopidogrelClopidogrel Bisulfate274$2,919
Carvedilol266$2,767
Isosorbide Mononitrate ErIsosorbide Mononitrate154$1,996

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →